Lundbeck

42.10 DKK

+0.67 %

Less than 1K followers

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

+0.67 %

-4.97 %

+7.51 %

-2.46 %

-2.27 %

+13.42 %

+11.73 %

+6.26 %

+71.14 %

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Market cap

41.92B DKK

Turnover

52.25M DKK

Revenue

24.63B

EBIT %

21.42 %

P/E

13.07

Dividend yield-%

2.73 %

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

19/8

2026

Interim report Q2'26

11/11

2026

Interim report Q3'26

3/2

2027

Annual report '26

All

Press releases

ShowingAll content types

Press release12 hours ago

H. Lundbeck A/S: Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

Press release5/18/2026, 8:03 AM

H. Lundbeck A/S: Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease

Regulatory press release5/12/2026, 9:22 AM

Strong start to 2026: +21% CER revenue growth (+13% CER underlying)

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release5/12/2026, 9:15 AM

H. Lundbeck A/S: Lundbeck raises financial guidance for 2026

Press release4/19/2026, 1:00 PM

H. Lundbeck A/S: Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)

Press release4/13/2026, 7:00 AM

H. Lundbeck A/S: Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Regulatory press release3/18/2026, 12:00 PM

H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 18 March 2026 at the company's registered office

Press release3/16/2026, 8:00 AM

H. Lundbeck A/S: Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Press release3/10/2026, 8:00 AM

H. Lundbeck A/S: Lundbeck appoints Chief AI Officer

Regulatory press release3/9/2026, 9:33 AM

H. Lundbeck A/S: Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial

Regulatory press release2/18/2026, 8:32 AM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Regulatory press release2/17/2026, 9:00 AM

To the shareholders of H. Lundbeck A/S

Regulatory press release2/12/2026, 3:39 PM

H. Lundbeck A/S: Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention

Regulatory press release2/6/2026, 10:39 AM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Regulatory press release2/4/2026, 6:13 PM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Regulatory press release2/4/2026, 6:50 AM

H. Lundbeck A/S: Lundbeck Annual Report 2025

Regulatory press release2/4/2026, 6:30 AM

H. Lundbeck A/S: Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026

Press release1/30/2026, 2:00 PM

H. Lundbeck A/S: Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference

Regulatory press release12/8/2025, 7:22 AM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Press release12/6/2025, 5:00 PM

H. Lundbeck A/S: Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.